Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs LillyDirect Foundayo

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, LillyDirect Foundayo a 75. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

LillyDirect Foundayo

#132 · Grade C+ · Fair Price

Est. first month

From $149/mo (brand Foundayo)

Get this deal Full LillyDirect Foundayo review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 75 an est. $149/mo first month, with no teaser step-up baked in. LillyDirect Foundayo isn't out of it: Patients with commercial insurance who want the cheapest legal brand-name GLP-1.

CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxLillyDirect Foundayo
Value Score93 (A+)75 (C+)
Est. first month$149/moFrom $149/mo (brand Foundayo)
Save vs brand-name~89%
Semaglutide$149/moNot disclosed
Tirzepatide$349/moNot disclosed
Both moleculesYesNo
PricingFlat — no step-upWatch
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
82
CoreAge Rx: 88. LillyDirect Foundayo: 82.
98
No Teaser-Rate Bait
72
CoreAge Rx: 98. LillyDirect Foundayo: 72.
98
Nationwide Availability
96
CoreAge Rx: 98. LillyDirect Foundayo: 96.
95
Both Molecules
45
CoreAge Rx: 95. LillyDirect Foundayo: 45.
95
Easy Cancellation
58
CoreAge Rx: 95. LillyDirect Foundayo: 58.
84
Reputation
95
CoreAge Rx: 84. LillyDirect Foundayo: 95.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

LillyDirect Foundayo

Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

Why it's a deal

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

The fine print

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow
Get the CoreAge Rx deal Get the LillyDirect Foundayo deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to LillyDirect Foundayo.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.